Fasoracetam: Mechanisms of Action and Clinical Research

Introduction

Fasoracetam (International Nonproprietary Name - INN) is an experimental drug of the racetam class that has never been brought to market but has attracted significant research attention due to its unique mechanism of action and therapeutic potential. The compound is also known by several code designations: NFC-1, NS-105, AEVI-001, LAM-105, NB-001, and MDGN-001. Unlike many other nootropics, fasoracetam demonstrates multi-level effects on neurotransmitter systems, opening prospects for its use in various psychiatric and neurological disorders. Originally developed by the Japanese company Nippon Shinyaku for the treatment of vascular dementia, the drug completed Phase III clinical trials but did not show sufficient efficacy for that indication, after which it was redirected toward other therapeutic targets.

Chemical Structure and Physicochemical Properties

Fasoracetam belongs to the class of racetams - compounds containing a five-membered oxopyrrolidine ring. The molecular formula of the drug is C₁₀H₁₆N₂O₂, with a molecular weight of 196.250 g/mol.

Research on the solid forms of fasoracetam conducted by Harmsen and colleagues (2017) revealed the existence of two hydrated and one anhydrous crystalline forms of the compound. Under ordinary conditions, the most stable form is hydrate form I, with a melting point of 57 °C. This low melting point, combined with potential water loss, may create challenges in drug formulation development and affect the storage conditions of the compound.

As part of the structural studies, a monohydrate form of fasoracetam was obtained with the molecular formula C₁₀H₁₆N₂O₂·H₂O and a molecular weight of 214.26 g/mol. The compound contains one stereocenter and exhibits optical activity.

Mechanism of Action

Fasoracetam is characterized by a multifaceted and unique mechanism of action that distinguishes it from many other nootropic drugs. The key component of its pharmacology is its function as a positive allosteric modulator of metabotropic glutamate receptors (mGluR). The drug activates mGluRs of all three groups, as confirmed by both preclinical and clinical studies.

Beyond modulation of the glutamatergic system, fasoracetam affects the GABAergic system. The drug interacts with GABA(B) receptors and can increase their expression. This mechanism is not found in other nootropics such as aniracetam. Additionally, fasoracetam stimulates neuronal acetylcholine receptors and influences acetylcholine release. Thus, the drug exerts a complex modulatory effect on both glutamatergic and GABAergic systems.

Pharmacokinetics

Fasoracetam demonstrates high oral bioavailability. In animal studies, it ranged from 79 to 97 %. The elimination half-life of the drug is between 4 and 6.5 hours.

In a clinical study involving adolescents with ADHD (2018), single-dose pharmacokinetic profiling was conducted across a dose range of 50 to 800 mg. Based on the data obtained, the subsequent 4-week phase of the study employed symptom-guided dose titration up to 400 mg twice daily.

Clinical Studies and Therapeutic Potential

Attention-Deficit/Hyperactivity Disorder (ADHD)

The most significant clinical data have been obtained from studies of fasoracetam in adolescents with ADHD. In 2018, the journal Nature Communications published the results of a 5-week open-label, single-blind, placebo-controlled study involving 30 adolescents aged 12-17 years with ADHD and mutations in genes of the metabotropic glutamatergic network (mGluR).

The study demonstrated statistically significant improvement in patient condition. Mean Clinical Global Impression-Improvement (CGI-I) scores improved from 3.79 at baseline to 2.33 by week 5 (P < 0.001). CGI-S (severity) scores decreased from 4.83 to 3.86 (P < 0.001). Parent ratings on the Vanderbilt scale also showed significant improvement in patients with level 1 mGluR variants (P < 0.035). The frequency of adverse events did not differ between placebo and active drug weeks.

In a later 2023 study published in the Journal of Neurodevelopmental Disorders, the authors confirmed that the non-stimulant mGluR activator fasoracetam is well-tolerated and may be useful for alleviating ADHD symptoms.

Fasoracetam is currently being studied in Phase II/III clinical trials for the treatment of ADHD in individuals with genetic disorders affecting mGlu receptors. Studies are being conducted in both patients with confirmed mGluR mutations and those without (clinical trial NCT03609619).

22q11.2 Deletion Syndrome

In 2025, results were published from a double-blind, multicenter, randomized, placebo-controlled crossover Phase II study conducted in North America from January 2022 to January 2023. The study enrolled 37 children and adolescents aged 6-17 years with 22q11.2 deletion syndrome (22q11DS) and clinical symptoms of attention deficits, anxiety, and/or social communication difficulties.

Fasoracetam (200 mg twice daily) demonstrated good tolerability: no serious adverse events were reported, and the frequency of mild and moderate adverse events did not differ between the fasoracetam and placebo groups (55 % vs. 71 %, respectively). CGI-I scores improved during fasoracetam treatment, and the response rate (defined as improvement on CGI-I) was 61 %. The authors concluded that fasoracetam is safe and well-tolerated in children with 22q11DS, and the positive trends in efficacy provide a basis for further research.

Anxiety Disorders

Fasoracetam is also being considered as a potential treatment for anxiety disorders. The drug's ability to increase the number of GABA(B) receptors and enhance inhibitory tone in the brain may contribute to anxiolytic and antidepressant-like effects. Patent documents describe methods for treating anxiety disorders using fasoracetam at doses ranging from 50 to 400 mg.

Safety and Tolerability

Clinical data indicate a favorable safety profile for fasoracetam. In the adolescent ADHD study, the frequency of adverse events did not differ between placebo and active drug periods. In the 22q11DS study, no serious adverse events were reported.

In studies of the solid forms of fasoracetam, it was noted that hydrate form I has a low melting point (57 °C), which may create challenges in drug formulation development and affect storage conditions. This must be considered when planning manufacturing and long-term storage of the drug.

Prospects and Directions for Further Research

Although fasoracetam did not demonstrate sufficient efficacy for vascular dementia, its unique mechanism of action opens new prospects. The most promising directions include:

1. Targeted therapy for ADHD in patients with genetic variants affecting the glutamatergic network. Given that copy number variations of mGluR genes are found in 11.3 % of children with ADHD compared to 1.2 % in the control group, fasoracetam may become a personalized approach to treating this subgroup of patients.

2. Treatment of neuropsychiatric symptoms in genetic syndromes such as 22q11.2 deletion, where the drug has shown promising results.

3. Anxiety disorders - given the drug's effects on GABA(B) receptors and inhibitory neuronal tone.

4. Other conditions associated with glutamatergic system dysfunction.

Conclusion

Fasoracetam is an experimental racetam-class drug with a unique, multifaceted mechanism of action that includes modulation of metabotropic glutamate receptors, interaction with GABA(B) receptors, and stimulation of the cholinergic system. Despite its failure in clinical trials for vascular dementia, the drug demonstrates promising results in the treatment of ADHD, particularly in patients with genetic variants affecting the glutamatergic network. Clinical data confirm good tolerability and a favorable safety profile for fasoracetam. Further research is needed to fully uncover the therapeutic potential of this compound and determine its place in clinical practice.